Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Pain
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Pain
    TopAbstracts in Pain 11/13/2008 - (DGNews)
    TopAbstracts in Pain 11/06/2008 - (DGNews)
    Functional MRI Reveals Relationship Between Depression and Pain - (DGNews)
    TopAbstracts in Pain 10/30/2008 - (DGNews)
    Foot orthoses and physiotherapy in the treatment of patellofemoral pain syndrome: randomised clinical trial - (BMJ)

    News archive

     Recent webcasts/CME - Pain
      Chronic Pain Management in Primary Care: Individualizing Pain Relief and Improving Quality of Life
      Acute Pain Management and Opioid Treatment: Community Pharmacist Perspectives
      Enhanced NSAID Delivery: Emerging Technologies
      Balanced Opioid Prescribing
      Persistent, Not Permanent: Alleviating Symptoms in Chronic Knee Pain

      Webcasts/CME archive

       Recent cases - Pain
        Sciatica Due to Extrapelvic Heterotopic Ossification: A Case Report
        Factitious Lymphoedema as a Psychiatric Condition Mimicking Reflex Sympathetic Dystrophy: A Case Report
        Gluteal Pyomyositis as a Rare Cause of Sciatica in a Temperate Region: A Case Report
        A Rare Cause of Forearm Pain: Anterior Branch of the Medial Antebrachial Cutaneous Nerve Injury: A Case Report
        An Unusual Presentation of Complex Regional Pain Syndrome Type I

        Cases archive
          




        my personal edition > pain > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Duloxetine Reduces Diabetic Neuropathic Pain, Even Without Comorbid Depression: Presented at AAPM

        By Paula Moyer

        PALM SPRINGS, FL -- February 28, 2005 -- The serotonin-norepinephrine reuptake inhibitor duloxetine (Cymbalta) reduces pain severity in diabetic patients with neuropathic pain, according to investigators speaking here on February 24th at the 21st annual meeting of the American Academy of Pain Medicine.

        "Duloxetine was superior to placebo in reducing pain severity … and night pain," reported principal investigator Joachim F. Wernicke, MD, PhD, Senior Research Physician, Eli Lilly and Company, Indianapolis, Indiana, United States. "It did not adversely affect glycemic control, lipid profiles, or electrophysiology assessments."

        He and his co-investigators were interested in duloxetine's potential to neuropathic pain in diabetics because serotonin and norepinephrine are both involved in pain modulation through descending inhibitory pathways in the brain and spinal cord.

        Therefore, they recruited 334 diabetic patients with neuropathic pain who were free from comorbid depression to participate in a 12-week study. The investigators randomized the patients to one of three treatment arms -- 60 mg of duloxetine once daily, 60 mg of duloxetine twice daily, or placebo.

        The researchers assessed response to treatment by weekly average score of 24-hour average pain severity on the 11-point Likert scale. The other assessments included pain severity at night and worst pain severity over a 24-hour period, as well as the Brief Pain Inventory (BPI), Clinical Global Impression of Severity (CGI-Severity), Patient Global Impression of Improvement (PGI-Improvement), the short-form McGill Pain Questionnaire, dynamic allodynia, and patients' average daily use of acetaminophen.

        Both doses of duloxetine resulted in significantly less pain than placebo by week 2, with continued divergence from placebo through the 12 weeks of the study (P <.001), Dr. Wernicke said. Separation from placebo was measurable by week 1 on the 24-hour average pain severity score.

        With the exception of allodynia, the investigators were also able to detect measurable changes in all other study outcomes for both doses of duloxetine that were better than those in the placebo arm, with no significant differences between the doses.

        Patients' 24-hour average pain severity was reduced as the direct result of the treatment effect, reported Dr. Wernicke (P <.001). The CGI and PGI evaluations also showed superior results with duloxetine, he added (P <.05 and P <.001, respectively).

        Duloxetine's efficacy was related to no detectable compromise of diabetic control as measured by hemoglobin A1c levels and significant hypoglycemic episodes per week. Lipid values were also unchanged after treatment, as assessed by low-density lipid cholesterol, high-density lipid cholesterol, and triglycerides.

        The researchers noted no difference among the three treatment groups regarding electrophysiology measures, reported Dr. Wernicke.

        Eli Lilly and Company manufactures the study drug and funded the study


        [Presentation title: Duloxetine at doses of 60 mg QD and 60 mg BID is effective treatment of diabetic neuropathic pain. Abstract 131]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send